COXEN
gemcitabine plus cisplatin; dose-dense MVAC in localized muscle-invasive bladder cancer
Clinician commentary on COXEN in the sources reviewed for this edition leads to one open question: What evidence and combined clinical assessment would justify adding, withholding or curtailing treatment without overstating a biomarker's clinical utility? Its leading findings: (1) A response biomarker is not, by itself, permission to omit cystectomy. (2) GC versus ddMVAC remains a conditional choice, not a settled equivalence or universal superiority claim. (3) adding perioperative IO versus reserving risk-adapted adjuvant IO remains a live sequencing dispute. 7 more findings follow. 203 sources screened, 66 cited; not all HCPs or all public discussion.
- NCT02177695 ↗
- v1.0.0 · edition 1
- updated Nov 1, 2026
- Deep
10 findings, and what sits behind each
01. A response biomarker is not, by itself, permission to omit cystectomy
39 statements · 17 passages · 7 sources · 8 named voices
Counterview: recorded · Limitations recorded: 3. Feeds the Medical Affairs question.
02. GC versus ddMVAC remains a conditional choice, not a settled equivalence or universal superiority claim
54 statements · 45 passages · 14 sources · 23 named voices
Counterview: recorded · Limitations recorded: 3. Feeds the Medical Affairs question.
Draws on: The comparison, Secondary endpoint: Pathologic T0 Rate Evaluation: Gemcitabine+Cisplatin (GC) Versus Dose-dense Methotrexate, Vinblastin, Doxorubicin, and Cisplatin (DDMVAC), Population and setting, Design and conduct, Safety and tolerability, Secondary endpoint: Value of Gene Expression Profiling in Predicting Overall Survival (OS).
03. Adding perioperative IO versus reserving risk-adapted adjuvant IO remains a live sequencing dispute
48 statements · 39 passages · 12 sources · 15 named voices
Counterview: recorded · Limitations recorded: 4. Feeds the Medical Affairs question.
Draws on: Secondary endpoint: Pathologic T0 Rate Evaluation: Gemcitabine+Cisplatin (GC) Versus Dose-dense Methotrexate, Vinblastin, Doxorubicin, and Cisplatin (DDMVAC).
04. ctDNA is described as strongly prognostic, but not yet a general rule for starting or stopping IO
17 statements · 11 passages · 5 sources · 6 named voices
Counterview: none recorded · Limitations recorded: 3. Feeds the Medical Affairs question.
05. Favorable prognosis after pCR is not the same as trial-level surrogacy for survival benefit
49 statements · 45 passages · 8 sources · 14 named voices
Counterview: recorded · Limitations recorded: 3. Feeds the Medical Affairs question.
Draws on: Secondary endpoint: Value of Gene Expression Profiling in Predicting Overall Survival (OS), The comparison.
06. Failure of the original treatment-specific COXEN objective did not erase the perceived value of S1314
47 statements · 34 passages · 18 sources · 14 named voices
Counterview: recorded · Limitations recorded: 3. Feeds the Medical Affairs question.
Draws on: Primary endpoint: Assessment of Whether the Treatment-specific COXEN Score is Prognostic of pT0 Rate, Design and conduct, Secondary endpoint: Predictability of the CO-eXpression ExtrapolatioN (COXEN) Score to Direct Which of the Two Regimens the Patient Should Receive: Gemcitabine+Cisplatin (GC) Versus Dose-dense Methotrexate, Vinblastin, Doxorubicin, and Cisplatin (DDMVAC), Secondary endpoint: Value of Gene Expression Profiling in Predicting Overall Survival (OS), Primary endpoint: Assessment of COXEN Score as a Predictive Factor Distinguishing Between GC and ddMVAC, Primary endpoint: Assessment of Whether the Treatment-specific COXEN Score is Prognostic of ≤ pT1 Rate, The comparison, Safety and tolerability.
07. Multimodal AI attracts strong enthusiasm, with clinical utility and external validation still unresolved
46 statements · 36 passages · 15 sources · 18 named voices
Counterview: recorded · Limitations recorded: 4. Feeds the Medical Affairs question.
08. cfDNA methylation is presented as exploratory proof of concept, not a validated reason to withhold chemotherapy
27 statements · 13 passages · 5 sources · 5 named voices
Counterview: none recorded · Limitations recorded: 4. Feeds the Medical Affairs question.
Draws on: Population and setting.
09. Prior BCG and secondary MIBC generate biological questions, not a current mandate to withhold cisplatin-based NAC
16 statements · 16 passages · 1 sources · 2 named voices
Counterview: none recorded · Limitations recorded: 3. Feeds the Medical Affairs question.
Draws on: Population and setting.
10. Referral, treatment delivery and local-treatment burden are part of the clinical question
19 statements · 18 passages · 7 sources · 9 named voices
Counterview: recorded · Limitations recorded: 3. Feeds the Medical Affairs question.
Draws on: The comparison, Safety and tolerability.
Counts overlap, since one statement can back several findings. They show what the report kept, not how many clinicians agree. The full report includes the interpretations and source links.
Select a finding to see what the full report holds for it: how many verified HCP statements and of what kind, the passages behind them, the sources and voices, and the counterview and limits it records. Select a part of the trial to see which findings draw on it.
- Finding 1 of 10
A response biomarker is not, by itself, permission to omit cystectomy
- statements
- 39
- passages
- 17
- sources
- 7
- named voices
- 8
What the statements areViews 27Questions and uncertainty 2Clinical experience 5Comparisons 2Restated results and context 3How passages are usedSupporting a statement 40Giving context 0Recorded with the finding- Counterview: recorded
- Limitations: 3
- Feeds the Medical Affairs question
- 5 posts and articles
- 2 podcasts and video
Not mapped to a part of the trial's registered design.
In the full report: the interpretation in full, all 39 statements cited to source and date, and the 7 sources linked where public.
Thicker lines mean more shared statements. A finding without a line goes beyond the registered design. Counts overlap, since one statement can back several findings, and they show what the report kept, not how many clinicians agree.
The full COXEN report gives each finding its interpretation, the attributed views behind it, counterviews, limits and the verified HCP statements, each linked to the original. Get a complete report free to see what you get.
What evidence and combined clinical assessment would justify adding, withholding or curtailing treatment without overstating a biomarker's clinical utility?
Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.
By the numbers
free- 203HCP commentary sources screened
- 66sources cited by verified HCP statements
- 62named in screened sources
- 61voices cited in the report
- 54cited voices matched to verified clinician profiles
Also in the sources: 5 organizational or shared accounts, not counted as people.
- 406verified statements, each linked to its source
- 201of them from speakers with a confirmed clinical role
- 10findings
Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context. No count estimates how many clinicians hold a view. Size (Deep) is set by the 406 verified statements. Statements from sponsors, hosts and organisations are labelled and count apart from identified clinicians. A confirmed clinical role is one verified by the NPI registry or by the person's own institution's staff page; a role a source only states is not counted.
What's inside
free| Section | Items | Access |
|---|---|---|
| Findings with interpretation, counterviews and limits | 10 | Titles free |
| Detailed analysis | 11 sections | Paid |
| Verified statements with short source quotes and links | 406 | Paid |
| Trial aspects mapped | 21 | Free |
| Sources with links | 66 | Counts free |
| Speaker attribution for cited voices | 61 | Paid |
Trial aspects
19 discussed · 2 no commentary · 0 incomplete| Aspect | Statements | Sources |
|---|---|---|
| Primary endpoint: Assessment of Whether the Treatment-specific COXEN Score is Prognostic of pT0 Rate | 7 | 3 |
| Primary endpoint: Assessment of Whether the Treatment-specific COXEN Score is Prognostic of ≤ pT1 Rate | 3 | 3 |
| Primary endpoint: Assessment of COXEN Score as a Predictive Factor Distinguishing Between GC and ddMVAC | 4 | 2 |
| Primary endpoint: Correlation Between GC-and ddMVAC-COXEN Scoreno commentary found | 0 | 0 |
| Secondary endpoint: Predictability of the CO-eXpression ExtrapolatioN (COXEN) Score to Direct Which of the Two Regimens the Patient Should Receive: Gemcitabine+Cisplatin (GC) Versus Dose-dense Methotrexate, Vinblastin, Doxorubicin, and Cisplatin (DDMVAC) | 6 | 3 |
| Secondary endpoint: Value of Gene Expression Profiling in Predicting Overall Survival (OS) | 5 | 3 |
| Secondary endpoint: Pathologic T0 Rate Evaluation: Gemcitabine+Cisplatin (GC) Versus Dose-dense Methotrexate, Vinblastin, Doxorubicin, and Cisplatin (DDMVAC) | 7 | 5 |
| Secondary endpoint: Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugsno commentary found | 0 | 0 |
| Population and setting | 9 | 5 |
| The comparison | 34 | 11 |
| Safety and tolerability | 4 | 4 |
| Design and conduct | 10 | 8 |
| DDR biomarkers, clinical complete response and bladder preservation | 44 | 10 |
| Pathological response as prognosis, early-phase endpoint and survival surrogate | 45 | 6 |
| Multimodal AI response prediction and interpretability | 34 | 14 |
| Exploratory plasma cfDNA methylation | 27 | 5 |
| Prior BCG, primary versus secondary MIBC and chemotherapy sensitivity | 16 | 1 |
| Perioperative IO, pathology-directed adjuvant treatment and evolving alternatives | 46 | 11 |
| ctDNA residual-risk assessment and decision-guiding limits | 16 | 4 |
| Referral, treatment uptake and cystectomy versus trimodality pathways | 18 | 6 |
| Molecular subtyping and the distinction between downstaging prediction and survival relevance | 3 | 2 |
An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.
Sources
free| Channel | Screened | Cited | |
|---|---|---|---|
| X threads | 191 | 53 | |
| YouTube | 8 | 7 | |
| Podcasts | 3 | 2 | |
| Bluesky threads | 1 | 0 | |
| Primary sources, cited for context, not screened | |||
| Publications | not screened | 3 | |
| Registry | not screened | 1 | |
max 28 / quarter
- Screened window
- Jul 22, 2014 → Sep 18, 2026
- Cited window
- Aug 14, 2014 → Jun 26, 2026
- Retrieved
- Oct 31, 2026
The trial
from ClinicalTrials.gov- Title
- A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer
- Also known as
- SWOG S1314
- Registry
- NCT02177695
- Study IDs
- S1314 · NCI-2014-00850 (National Cancer Institute) · U10CA180888
- Sponsor
- SWOG Cancer Research Network
- Collaborators
- National Cancer Institute (NCI)
- Design
- Phase 2 · Interventional, randomized, parallel
- Status
- Completed
- Enrollment
- 237 actual
- Registered
- 2014-06-30
- Start
- 2014-08-28 actual
- Primary completion
- 2020-02 actual
- Primary endpoint
- Assessment of Whether the Treatment-specific COXEN Score is Prognostic of pT0 Rate
- Interventions
- 6 registered
Scope and limits
freeThis report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.
- Discussion that does not name the trial may be missing from this edition.
- 1 cited commentary passage leaves a source question open, such as who was speaking. The report attributes no further than the source shows.
- Not yet captured in this edition: a view on survival evidence informing neoadjuvant versus adjuvant immunotherapy alongside chemotherapy and surgery.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 320 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits apply, so some matching discussion may be missing.
- The sources reviewed for this edition do not represent all HCP discussion or support estimates of professional consensus. Multiple posts, reposts or sources are not necessarily independent assessments.
- Trial-name and identifier-focused discovery may miss discussions using unnamed references or different transcription variants. Some available passages were not fully assessed for clinician views, so absence from an aspect is not proof that the issue was never discussed.
- Some spoken passages cannot be assigned to a named participant. They may belong to a named participant in the same program and must not be counted as additional voices.
- A relay preserves another party's statement; it does not establish that the relayer independently endorses the interpretation. Research involvement, professional identity or an organizational account does not increase evidentiary weight.
- The discussions span different evidence maturities, populations and treatment-access circumstances. Approval, reimbursement, investigational status and anticipated readouts are time-specific, not a current comprehensive regulatory assessment.
- S1314 was not designed to settle all secondary regimen or response–survival comparisons, and reduced biomarker evaluability limits precision. Nonsignificance is not equivalence, and prognostic association is not proof of treatment-selection benefit.
- Gene-panel descriptions, unusual regimen wording and methylation performance percentages are not fully consistent across sources. The report preserves those differences rather than selecting an unverified correction.
- Unclear wording about patients not proceeding to surgery does not establish progression, toxicity or another specific clinical reason.
How reports are built and checked: Methods.
Editions and corrections
freeLast checked for new commentary Nov 1, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update. No corrections.
Cite this report
Erudio Health. COXEN (NCT02177695): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 1, 2026. https://www.erudio.com/reports/coxen-nct02177695
For your AI agent
Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.
Help me decide whether to buy the Erudio report "COXEN" (NCT02177695), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.
1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "coxen-02177695". If you cannot make requests, read https://www.erudio.com/reports/coxen-nct02177695.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email and the product: the current edition, or 3, 6 or 12 months of weekly updates. Call create_order with report "NCT02177695", that product and email, then show me the quote and the checkout_url to pay by card. If you have a payment client for HTTP 402 payments and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id erudio-nct02177695 and sections ["all"], and summarize the findings for me with their sources. The full report is large (about 500 KB): save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.
When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.Or read the record directly: JSON, Markdown or MCP
curl https://www.erudio.com/reports/coxen-nct02177695.json
curl https://www.erudio.com/reports/coxen-nct02177695.md
# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "coxen-02177695" })release d859d3cb5a3422d2b0c7f7a730e41e92d7ac37c4d610c0b36450c12ca64d07c1